The global cardiovascular, renal, and metabolic (CRM) diseases market, valued at US$298.73 billion in 2024, is projected to reach US$451.87 billion by 2033 at a 4.8% CAGR. Explore drivers like rising comorbidities (one-third of patients affected by two+ conditions), aging populations, and therapies such as SGLT-2 inhibitors amid advances in combination treatments and early diagnostics. https://finance.yahoo.com/news/cardiovascular-renal-metabolic-crm-diseases-143500544.html